Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M176,452Revenue $M50,387Net Margin (%)35.5Altman Z-Score2.5
Enterprise Value $M193,919EPS $7.3Operating Margin %17.8Piotroski F-Score5
P/E(ttm)10.2Beneish M-Score-2.3Pre-tax Margin (%)16.1Higher ROA y-yY
Price/Book2.310-y EBITDA Growth Rate %1.4Quick Ratio0.6Cash flow > EarningsN
Price/Sales3.55-y EBITDA Growth Rate %-0.4Current Ratio0.9Lower Leverage y-yY
Price/Free Cash Flow19.4y-y EBITDA Growth Rate %-7.5ROA % (ttm)13.5Higher Current Ratio y-yN
Dividend Yield %3.6PEG--ROE % (ttm)23.5Less Shares Outstanding y-yY
Payout Ratio %93.0Shares Outstanding M2,374ROIC % (ttm)8.4Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSKen Fisher 2015-12-31 Add0.01%$83.96 - $95.03
($88.6)
$ 74.33-16%Add 0.92%6,188,893
NVSMario Gabelli 2015-12-31 Reduce$83.96 - $95.03
($88.53)
$ 74.33-16%Reduce -1.99%7,390
NVSDodge & Cox 2015-09-30 Reduce-0.2%$89.52 - $106.12
($99.32)
$ 74.33-25%Reduce -4.68%45,723,035
NVSKen Fisher 2015-09-30 Add0.02%$89.52 - $106.12
($99.32)
$ 74.33-25%Add 1.28%6,132,211
NVSTweedy Browne 2015-09-30 Reduce-0.01%$89.52 - $106.12
($99.32)
$ 74.33-25%Reduce -2.04%249,022
NVSKahn Brothers 2015-09-30 Add0.01%$89.52 - $106.12
($99.32)
$ 74.33-25%Add 1.42%28,543
NVSMario Gabelli 2015-09-30 Reduce$89.52 - $106.12
($99.32)
$ 74.33-25%Reduce -9.48%7,540
NVSDodge & Cox 2015-06-30 Reduce-0.19%$98.34 - $105.5
($102.32)
$ 74.33-27%Reduce -4.12%47,970,345
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 74.33-27%Reduce -9.12%28,143
NVSTweedy Browne 2015-06-30 Reduce-0.02%$98.34 - $105.5
($102.32)
$ 74.33-27%Reduce -2.31%254,217
NVSKen Fisher 2015-06-30 Add0.01%$98.34 - $105.5
($102.32)
$ 74.33-27%Add 1.08%6,054,640
NVSMario Gabelli 2015-06-30 Reduce$98.34 - $105.5
($102.32)
$ 74.33-27%Reduce -15.35%8,330
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 74.33-25%Reduce -0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 74.33-25%Reduce -2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.99)
$ 74.33-25%Sold Out0
NVSMario Gabelli 2015-03-31 Add$91.67 - $103
($98.99)
$ 74.33-25%Add 2.61%9,840
NVSKen Fisher 2015-03-31 Reduce$91.67 - $103
($98.99)
$ 74.33-25%Reduce -0.29%5,990,224
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 74.33-20%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 74.33-18%Reduce -98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 74.33-18%New holding7,772
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15395.53view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    Valeant's Share Price Continues to Decline Feb 05 2016 
    10 Fund Managers Are Totally Wrong on GlaxoSmithKline Jan 26 2016 
    Guru Stocks at 52-Week Lows Jan 26 2016 
    Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows Jan 11 2016 
    Berkshire Hathaway, China Mobile, Novartis, Oracle, PetroChina Near 52-Week Lows Jan 04 2016 
    Guru Stocks at 52-Week Lows: NVS, WMT, IBM, AXP, CHU Nov 01 2015 
    Signature Select Canadian Fund Second Quarter 2015 Market Commentary Sep 22 2015 
    Valeant Pharmaceuticals' New Female Drug Aug 20 2015 
    Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
    Bill Frels' Stocks With Growing Yields Jun 27 2015 

    More From Other Websites
    After The Martin Shkreli Circus, How Can We Fix Drug Pricing? Feb 04 2016
    [$$] Activist investors: hard drugs Feb 04 2016
    Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact Feb 04 2016
    Novartis AG Earnings Analysis: 2015 By the Numbers Feb 04 2016
    Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis Feb 04 2016
    Morgan Freeman Visits DC On Cancer Prevention Day To Bring Good News: 70% Of Cancers Are Preventable Feb 04 2016
    [$$] GlaxoSmithKline: Playing the Waiting Game Feb 03 2016
    Eli Lilly and Co.’s 4Q15 Earnings: An Overview Feb 03 2016
    [$$] Investors' Fears Eased as Glaxo Posts Solid Results Feb 03 2016
    [$$] GlaxoSmithKline rules out break up as new drugs boost sales Feb 03 2016
    GSK refuses to be bounced into early consumer unit spin-off Feb 03 2016
    GSK refuses to be bounced into early consumer unit spin-off Feb 03 2016
    GSK refuses to be bounced into early consumer unit spin-off Feb 03 2016
    Drugs giant GSK says annual net profits triple Feb 03 2016
    Drugs giant GSK says annual net profits triple Feb 02 2016
    Sun hopes cut-price generic Gleevec will win third of U.S. market Feb 01 2016
    Sun hopes cut-price generic Gleevec will win third of U.S. market Feb 01 2016
    Sun hopes cut-price generic Gleevec will win third of U.S. market Feb 01 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK